Recent advances in targeting the autotaxin-lysophosphatidate-lipid phosphate phosphatase axis in vivo

Journal of Biomedical Research

Volumn 30, Issue 4, 2016, Pages 272-284

  Benesch, Matthew G K ^a   Tang, Xiaoyun ^a   Venkatraman, Ganesh ^a   Bekele, Raie T ^a   Brindley, David N ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cancer; Chronic inflammation; Cytokines; Monoclonal antibodies; Wound repair

Indexed keywords

AM 152; AM 966; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; AUTOTAXIN; BMS 986020; BMS 986202; LIPID PHOSPHATE PHOSPHATASE; LPATHOMAB; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID RECEPTOR; MONOCLONAL ANTIBODY; ONO 8430506; PF 8380; PHOSPHATASE; SAR 100842; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; CANCER CELL; CANCER INHIBITION; CANCER THERAPY; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

EID: 84992411981     PISSN: 16748301     EISSN: None     Source Type: Journal    
DOI: 10.7555/JBR.30.20150058     Document Type: Review

References (152)

1. Croset M, Brossard N, Polette A, et al. Characterization of plasma unsaturated lysophosphatidylcholines in human and rat[J]. Biochem J, 2000, 345(Pt 1): 61-67
2. Wiesner P, Leidl K, Boettcher A, et al. Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry[J]. J Lipid Res, 2009, 50(3): 574-585
3. Eichholtz T, Jalink K, Fahrenfort I, et al. The bioactive phospholipid lysophosphatidic acid is released from activated platelets[J]. Biochem J, 1993, 291 (Pt 3): 677-680
4. Tigyi G, Miledi R. Lysophosphatidates bound to serum albumin activate membrane currents in Xenopus oocytes and neurite retraction in PC12 pheochromocytoma cells[J]. J Biol Chem, 1992, 267(30): 21360-21367
5. Baker DL, Morrison P, Miller B, et al. Plasma lysophosphatidic acid concentration and ovarian cancer[J]. JAMA, 2002, 287(23): 3081-3082
6. Nakanaga K, Hama K, Aoki J. Autotaxin-an LPA producing enzyme with diverse functions[J]. J Biochem, 2010, 148(1): 13-24
7. Brindley DN, Lin FT, Tigyi GJ. Role of the autotaxin-lysophosphatidate axis in cancer resistance to chemotherapy and radiotherapy[J]. Biochim Biophys Acta, 2013, 1831(1): 74-85
8. Gaetano CG, Samadi N, Tomsig JL, et al. Inhibition of autotaxin production or activity blocks lysophosphatidylcholine-induced migration of human breast cancer and melanoma cells[J]. Mol Carcinog, 2009, 48(9): 801-809
9. Samadi N, Gaetano C, Goping IS, et al. Autotaxin protects MCF-7 breast cancer and MDA-MB-435 melanoma cells against Taxol-induced apoptosis[J]. Oncogene, 2009, 28(7): 1028-1039
10. Kok BP, Venkatraman G, Capatos D, et al. Unlike two peas in a pod: lipid phosphate phosphatases and phosphatidate phosphatases[J]. Chem Rev, 2012, 112(10): 5121-5146
11. Jamal Z, Martin A, Gomez-Munoz A, et al. Plasma membrane fractions from rat liver contain a phosphatidate phosphohydrolase distinct from that in the endoplasmic reticulum and cytosol[J]. J Biol Chem, 1991, 266(5): 2988-2996
12. Brindley DN, Waggoner DW. Mammalian lipid phosphate phosphohydrolases[J]. J Biol Chem, 1998, 273(38): 24281-24284
13. Jasinska R, Zhang QX, Pilquil C, et al. Lipid phosphate phosphohydrolase-1 degrades exogenous glycerolipid and sphingolipid phosphate esters[J]. Biochem J, 1999, 340 (Pt 3): 677-686
14. Bekele R, Brindley DN. Role of autotaxin and lysophosphatidate in cancer progression and resistance to chemotherapy and radiotherapy[J]. Clin Lipidol, 2012, 7: 313-328
15. Samadi N, Bekele R, Capatos D, et al. Regulation of lysophosphatidate signaling by autotaxin and lipid phosphate phosphatases with respect to tumor progression, angiogenesis, metastasis and chemo-resistance[J]. Biochimie, 2011, 93(1): 61-70
16. Panchatcharam M, Salous AK, Brandon J, et al. Mice with targeted inactivation of ppap2b in endothelial and hematopoietic cells display enhanced vascular inflammation and permeability[J]. Arterioscler Thromb Vasc Biol, 2014, 34(4): 837-845
17. Smyth SS, Mueller P, Yang F, et al. Arguing the case for the autotaxin-lysophosphatidic acid-lipid phosphate phosphatase 3-signaling nexus in the development and complications of atherosclerosis[J]. Arterioscler Thromb Vasc Biol, 2014, 34(3): 479-486
18. Akira T, Kengo H, Kenji F, et al. Involvement of lysophospholipase D in the production of lysophosphatidic acid in rat plasma[J]. Biochim Biophys Acta, 1986, 875(1): 31-38
19. Stracke ML, Krutzsch HC, Unsworth EJ, et al. Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein[J]. J Biol Chem, 1992, 267(4): 2524-2529
20. Murata J, Lee HY, Clair T, et al. cDNA cloning of the human tumor motility-stimulating protein, autotaxin, reveals a homology with phosphodiesterases[J]. J Biol Chem, 1994, 269(48): 30479-30484
21. Buckley MF, Loveland KA, McKinstry WJ, et al. Plasma cell membrane glycoprotein PC-1. cDNA cloning of the human molecule, amino acid sequence, and chromosomal location[J]. J Biol Chem, 1990, 265(29): 17506-17511
22. Funakoshi I, Kato H, Horie K, et al. Molecular cloning of cDNAs for human fibroblast nucleotide pyrophosphatase[J]. Arch Biochem Biophys, 1992, 295(1): 180-187
23. Kawagoe H, Soma O, Goji J, et al. Molecular cloning and chromosomal assignment of the human brain-type phosphodiesterase I/nucleotide pyrophosphatase gene (PDNP2)[J]. Genomics, 1995, 30(2): 380-384
24. Umezu-Goto M, Kishi Y, Taira A, et al. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production[J]. J Cell Biol, 2002, 158(2): 227-233
25. Tokumura A, Majima E, Kariya Y, et al. Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase[J]. J Biol Chem, 2002, 277(42): 39436-39442
26. Moolenaar WH. Lysophospholipids in the limelight: autotaxin takes center stage[J]. J Cell Biol, 2002, 158(2): 197-199
27. Hama K, Aoki J, Fukaya M, et al. Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1[J]. J Biol Chem, 2004, 279(17): 17634-17639
28. van Meeteren LA, Ruurs P, Stortelers C, et al. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development[J]. Mol Cell Biol, 2006, 26(13): 5015-5022
29. Koike S, Keino-Masu K, Masu M. Deficiency of autotaxin/lysophospholipase D results in head cavity formation in mouse embryos through the LPA receptor-Rho-ROCK pathway[J]. Biochem Biophys Res Commun, 2010, 400(1): 66-71
30. Koike S, Keino-Masu K, Ohto T, et al. Autotaxin/lysophospholipase D-mediated lysophosphatidic acid signaling is required to form distinctive large lysosomes in the visceral endoderm cells of the mouse yolk sac[J]. J Biol Chem, 2009, 284(48): 33561-33570
31. Koike S, Yutoh Y, Keino-Masu K, et al. Autotaxin is required for the cranial neural tube closure and establishment of the midbrain-hindbrain boundary during mouse development[ J]. Dev Dyn, 2011, 240(2): 413-421
32. Moolenaar WH, Houben AJ, Lee SJ, et al. Autotaxin in embryonic development[J]. Biochim Biophys Acta, 2013, 1831(1): 13-19
33. Tanaka M, Okudaira S, Kishi Y, et al. Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid[J]. J Biol Chem, 2006, 281(35): 25822-25830
34. Fotopoulou S, Oikonomou N, Grigorieva E, et al. ATX expression and LPA signalling are vital for the development of the nervous system[J]. Dev Biol, 2010, 339(2): 451-464
35. Yukiura H, Hama K, Nakanaga K, et al. Autotaxin regulates vascular development via multiple lysophosphatidic acid (LPA) receptors in zebrafish[J]. J Biol Chem, 2011, 286(51): 43972-43983
36. Yuelling LW, Waggener CT, Afshari FS, et al. Autotaxin/ENPP2 regulates oligodendrocyte differentiation in vivo in the developing zebrafish hindbrain[J]. Glia, 2012, 60(10): 1605-1618
37. Lai SL, Yao WL, Tsao KC, et al. Autotaxin/Lpar3 signaling regulates Kupffer's vesicle formation and left-right asymmetry in zebrafish[J]. Development, 2012, 139(23): 4439-4448
38. Cheng HY, Dong A, Panchatcharam M, et al. Lysophosphatidic acid signaling protects pulmonary vasculature from hypoxia-induced remodeling[J]. Arterioscler Thromb Vasc Biol, 2012, 32(1): 24-32
39. Brindley DN. Lipid phosphate phosphatases and related proteins: signaling functions in development, cell division, and cancer[J]. J Cell Biochem, 2004, 92(5): 900-912
40. Mazereeuw-Hautier J, Gres S, Fanguin M, et al. Production of lysophosphatidic acid in blister fluid: involvement of a lysophospholipase D activity[J]. J Invest Dermatol, 2005, 125(3): 421-427
41. Tokumura A, Taira S, Kikuchi M, et al. Lysophospholipids and lysophospholipase D in rabbit aqueous humor following corneal injury[J]. Prostaglandins Other Lipid Mediat, 2012, 97(3-4): 83-89
42. Grisanti L, Rezza A, Clavel C, et al. Enpp2/Autotaxin in dermal papilla precursors is dispensable for hair follicle morphogenesis[J]. J Invest Dermatol, 2013, 133(10): 2332-2339
43. Mebarek S, Abousalham A, Magne D, et al. Phospholipases of mineralization competent cells and matrix vesicles: roles in physiological and pathological mineralizations[ J]. Int J Mol Sci, 2013, 14(3): 5036-5129
44. Evseenko D, Latour B, Richardson W, et al. Lysophosphatidic acid mediates myeloid differentiation within the human bone marrow microenvironment[J]. PLoS One, 2013, 8(5): e63718
45. Masuda K, Haruta S, Orino K, et al. Autotaxin as a novel, tissue-remodeling-related factor in regressing corpora lutea of cycling rats[J]. FEBS J, 2013, 280: 6600-6612
46. Awada R, Rondeau P, Gres S, et al. Autotaxin protects microglial cells against oxidative stress[J]. Free Radic Biol Med, 2012, 52(2): 516-526
47. Awada R, Saulnier-Blache JS, Gres S, et al. Autotaxin downregulates LPS-induced microglia activation and proinflammatory cytokines production[J]. J Cell Biochem, 2014, 115(12): 2123-2132
48. Umemoto E, Hayasaka H, Bai Z, et al. Novel regulators of lymphocyte trafficking across high endothelial venules[J]. Crit Rev Immunol, 2011, 31(2): 147-169
49. Bai Z, Cai L, Umemoto E, et al. Constitutive lymphocyte transmigration across the basal lamina of high endothelial venules is regulated by the autotaxin/lysophosphatidic acid axis[J]. J Immunol, 2013, 190(5): 2036-2048
50. Zhang Y, Chen YC, Krummel MF, et al. Autotaxin through lysophosphatidic acid stimulates polarization, motility, and transendothelial migration of naive T cells[J]. J Immunol, 2012, 189(8): 3914-3924
51. Knowlden S, Georas SN. The autotaxin-LPA axis emerges as a novel regulator of lymphocyte homing and inflammation[ J]. J Immunol, 2014, 192(3): 851-857
52. Nakasaki T, Tanaka T, Okudaira S, et al. Involvement of the lysophosphatidic acid-generating enzyme autotaxin in lymphocyte-endothelial cell interactions[J]. Am J Pathol, 2008, 173(5): 1566-1576
53. van Meeteren LA, Moolenaar WH. Regulation and biological activities of the autotaxin-LPA axis[J]. Prog Lipid Res, 2007, 46(2): 145-160
54. Budd DC, Qian Y. Development of lysophosphatidic acid pathway modulators as therapies for fibrosis[J]. Future Med Chem, 2013, 5(16): 1935-1952
55. Benesch MGK, Zhao YY, Curtis JM, et al. Regulation of autotaxin expression by lysophosphatidate and sphingosine 1-phosphate[J]. J Lipid Res, 2015: doi:10.1194/jlr.M057661
56. Benesch MGK, Ko YM, McMullen TPW, et al. Autotaxin in the crosshairs: Taking aim at cancer and other inflammatory conditions[J]. FEBS Lett, 2014,588(16): 2712-2727
57. Bollen M, Gijsbers R, Ceulemans H, et al. Nucleotide pyrophosphatases/phosphodiesterases on the move[J]. Crit Rev Biochem Mol Biol, 2000, 35(6): 393-432
58. Debies MT, Welch DR. Genetic basis of human breast cancer metastasis[J]. J Mammary Gland Biol Neoplasia, 2001, 6(4): 441-451
59. Moolenaar WH, van Meeteren LA, Giepmans BN. The ins and outs of lysophosphatidic acid signaling[J]. Bioessays, 2004, 26(8): 870-881
60. Gendaszewska-Darmach E. Lysophosphatidic acids, cyclic phosphatidic acids and autotaxin as promising targets in therapies of cancer and other diseases[J]. Acta Biochim Pol, 2008, 55(2): 227-240
61. Liu S, Murph M, Panupinthu N, et al. ATX-LPA receptor axis in inflammation and cancer[J]. Cell Cycle, 2009, 8(22): 3695-3701
62. Panupinthu N, Lee HY, Mills GB. Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression[J]. Br J Cancer, 2010, 102(6): 941-946
63. Houben AJ, Moolenaar WH. Autotaxin and LPA receptor signaling in cancer[J]. Cancer Metastasis Rev, 2011, 30 (3-4): 557-565
64. Gotoh M, Fujiwara Y, Yue J, et al. Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis[J]. Biochem Soc Trans, 2012, 40(1): 31-36
65. Peyruchaud O, Leblanc R, David M. Pleiotropic activity of lysophosphatidic acid in bone metastasis[J]. Biochim Biophys Acta, 2013, 1831(1): 99-104
66. So J, Wang FQ, Navari J, et al. LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2)[J]. Gynecol Oncol, 2005, 97(3): 870-878
67. Murph MM, Hurst-Kennedy J, Newton V, et al. Lysophosphatidic acid decreases the nuclear localization and cellular abundance of the p53 tumor suppressor in A549 lung carcinoma cells[J]. Mol Cancer Res, 2007, 5(11): 1201-1211
68. Samadi N, Bekele RT, Goping IS, et al. Lysophosphatidate induces chemo-resistance by releasing breast cancer cells from taxol-induced mitotic arrest[J]. PLoS One, 2011, 6(5): e20608
69. Zhang R, Wang J, Ma S, et al. Requirement of Osteo-pontin in migration and the protection against Taxol-induced apoptosis via ATX-LPA axis in SGC7901 cells[J]. BMC Cell Biol, 2011, 12(1): 11
70. Vidot S, Witham J, Agarwal R, et al. Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells[J]. Cell Signal, 2010, 22(6): 926-935
71. Deng W, Shuyu E, Tsukahara R, et al. The lysophosphatidic acid type 2 receptor is required for protection against radiation-induced intestinal injury[J]. Gastroenterology, 2007, 132(5): 1834-1851
72. Liu S, Umezu-Goto M, Murph M, et al. Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases[J]. Cancer Cell, 2009, 15(6): 539-550
73. Euer N, Schwirzke M, Evtimova V, et al. Identification of genes associated with metastasis of mammary carcinoma in metastatic versus non-metastatic cell lines[J]. Anticancer Res, 2002, 22(2A): 733-740
74. St-Coeur PD, Ferguson D, Morin P, Jr., et al PF-8380 and closely related analogs: synthesis and structure-activity relationship towards autotaxin inhibition and glioma cell viability[J]. Arch Pharm, 2013, 346(2): 91-97
75. Popnikolov NK, Dalwadi BH, Thomas JD, et al. Association of autotaxin and lysophosphatidic acid receptor 3 with aggressiveness of human breast carcinoma[J]. Tumour Biol, 2012, 33(6): 2237-2243
76. Benesch MGK, Tang X, Maeda T, et al. Inhibition of autotaxin delays breast tumor growth and lung metastasis in mice[J]. FASEB J, 2014, 28(6): 2655-2666
77. Leblanc R, Lee SC, David M, et al. Interaction of plateletderived autotaxin with tumor integrin alphaVbeta3 controls metastasis of breast cancer cells to bone[J]. Blood, 2014, 124(20): 3141-3150
78. Brindley DN, Benesch MGK, Murph MM. Autotaxin-An Enzymatic Augmenter of Malignant Progression Linked to Inflammation. Melanoma-Current Clinical Management and Future Therapeutics: InTech Open. 2015: 297-324. doi:210.5772/59013
79. Barbayianni E, Kaffe E, Aidinis V, et al. Autotaxin, a secreted lysophospholipase D, as a promising therapeutic target in chronic inflammation and cancer[J]. Prog Lipid Res, 2015, 58: 76-96
80. Chun J, Hla T, Lynch KR, et al. International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature[J]. Pharmacol Rev, 2010, 62(4): 579-587
81. Hecht JH, Weiner JA, Post SR, et al. Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex[J]. J Cell Biol, 1996, 135(4): 1071-1083
82. An S, Bleu T, Huang W, et al. Identification of cDNAs encoding two G protein-coupled receptors for lysosphingolipids[ J]. FEBS Lett, 1997, 417(3): 279-282
83. An S, Bleu T, Hallmark OG, et al. Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid[J]. J Biol Chem, 1998, 273(14): 7906-7910
84. Bandoh K, Aoki J, Hosono H, et al. Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid[J]. J Biol Chem, 1999, 274(39): 27776-27785
85. Ye X, Skinner MK, Kennedy G, et al. Age-Dependent Loss of Sperm Production in Mice via Impaired Lysophosphatidic Acid Signaling[J]. Biol Reprod, 2008, 79(2): 328-336
86. Contos JJA, Ishii I, Fukushima N, et al. Characterization of lpa2 (Edg4) and lpa1/lpa2 (Edg2/Edg4) Lysophosphatidic Acid Receptor Knockout Mice: Signaling Deficits without Obvious Phenotypic Abnormality Attributable to lpa2[J]. Mol Cell Biol, 2002, 22(19): 6921-6929
87. Contos JJ, Fukushima N, Weiner JA, et al. Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behavior[J]. Proc Natl Acad Sci U S A, 2000, 97(24): 13384-13389
88. Ye X, Hama K, Contos JJ, et al. LPA3-mediated lysophosphatidic acid signalling in embryo implantation and spacing[ J]. Nature, 2005, 435(7038): 104-108
89. Contos JJ, Ishii I, Fukushima N, et al. Characterization of lpa(2) (Edg4) and lpa(1)/lpa(2) (Edg2/Edg4) lysophosphatidic acid receptor knockout mice: signaling deficits without obvious phenotypic abnormality attributable to lpa(2)[J]. Mol Cell Biol, 2002, 22(19): 6921-6929
90. Yung YC, Stoddard NC, Chun J. LPA receptor signaling: pharmacology, physiology, and pathophysiology[J]. J Lipid Res, 2014, 55(7): 1192-1214
91. Ohuchi H, Hamada A, Matsuda H, et al. Expression patterns of the lysophospholipid receptor genes during mouse early development[J]. Dev Dyn, 2008, 237(11): 3280-3294
92. Choi JW, Herr DR, Noguchi K, et al. LPA receptors: subtypes and biological actions[J]. Annu Rev Pharmacol Toxicol, 2010, 50: 157-186
93. Meyerzu Heringdorf D, Jakobs KH. Lysophospholipid receptors: signalling, pharmacology and regulation by lysophospholipid metabolism[J]. Biochim Biophys Acta, 2007, 1768(4): 923-940
94. Lundequist A, Boyce JA. LPA5 is abundantly expressed by human mast cells and important for lysophosphatidic acid induced MIP-1beta release[J]. PLoS One, 2011, 6(3): e18192
95. Lee Z, Cheng CT, Zhang H, et al. Role of LPA4/p2y9/GPR23 in negative regulation of cell motility[J]. Mol Biol Cell, 2008, 19(12): 5435-5445
96. Lin ME, Rivera RR, Chun J. Targeted deletion of LPA5 identifies novel roles for lysophosphatidic acid signaling in development of neuropathic pain[J]. J Biol Chem, 2012, 287(21): 17608-17617
97. Pasternack SM, von Kugelgen I, Al Aboud K, et al. G proteincoupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth[J]. Nat Genet, 2008, 40(3): 329-334
98. Lee M, Choi S, Hallden G, et al. P2Y5 is a G(alpha)i, G(alpha)12/13 G protein-coupled receptor activated by lysophosphatidic acid that reduces intestinal cell adhesion[ J]. Am J Physiol Gastrointest Liver Physiol, 2009, 297(4): G641-654
99. Furui T, LaPushin R, Mao M, et al. Overexpression of edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner[J]. Clin Cancer Res, 1999, 5(12): 4308-4318
100. Pustilnik TB, Estrella V, Wiener JR, et al. Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells[J]. Clin Cancer Res, 1999, 5(11): 3704-3710
101. Shida D, Kitayama J, Yamaguchi H, et al. Lysophosphatidic acid (LPA) enhances the metastatic potential of human colon carcinoma DLD1 cells through LPA1[J]. Cancer Res, 2003, 63(7): 1706-1711
102. Schulte KM, Beyer A, Kohrer K, et al. Lysophosphatidic acid, a novel lipid growth factor for human thyroid cells: over-expression of the high-affinity receptor edg4 in differentiated thyroid cancer[J]. Int J Cancer, 2001, 92(2): 249-256
103. Kitayama J, Shida D, Sako A, et al. Over-expression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma[J]. Breast Cancer Res, 2004, 6(6): R640-646
104. Shida D, Watanabe T, Aoki J, et al. Aberrant expression of lysophosphatidic acid (LPA) receptors in human colorectal cancer[J]. Lab Invest, 2004, 84(10): 1352-1362
105. Okabe K, Hayashi M, Kato K, et al. Lysophosphatidic acid receptor-3 increases tumorigenicity and aggressiveness of rat hepatoma RH7777 cells[J]. Mol Carcinog, 2013, 52(4): 247-254
106. Okabe K, Hayashi M, Yamawaki Y, et al. Possible involvement of lysophosphatidic acid receptor-5 gene in the acquisition of growth advantage of rat tumor cells[J]. Mol Carcinog, 2011, 50(8): 635-642
107. Lee SC, Fujiwara Y, Liu J, et al. Autotaxin and LPA1 and LPA5 Receptors Exert Disparate Functions in Tumor Cells versus the Host Tissue Microenvironment in Melanoma Invasion and Metastasis[J]. Mol Cancer Res, 2015, 13(1): 174-185
108. Kihara Y, Mizuno H, Chun J. Lysophospholipid receptors in drug discovery[J]. Exp Cell Res, 2014: doi:10.1016/j.yexcr.2014.1011.1020
109. Stoddard NC, Chun J. Promising pharmacological directions in the world of lysophosphatidic Acid signaling[J]. Biomol Ther (Seoul), 2015, 23(1): 1-11
110. Tang X, Benesch MG, Brindley DN. Lipid phosphate phosphatases and their roles in mammalian physiology and pathology[J]. J Lipid Res, 2015: doi:10.1194/jlr.R058362
111. Tomsig JL, Snyder AH, Berdyshev EV, et al. Lipid phosphate phosphohydrolase type 1 (LPP1) degrades extracellular lysophosphatidic acid in vivo[J]. Biochem J, 2009, 419(3): 611-618
112. Barila D, Plateroti M, Nobili F, et al. The Dri 42 gene, whose expression is up-regulated during epithelial differentiation, encodes a novel endoplasmic reticulum resident transmembrane protein[J]. J Biol Chem, 1996, 271(47): 29928-29936
113. Kai M, Wada I, Imai S, et al. Cloning and characterization of two human isozymes of Mg2+-independent phosphatidic acid phosphatase[J]. J Biol Chem, 1997, 272(39): 24572-24578
114. Pyne S, Kong KC, Darroch PI. Lysophosphatidic acid and sphingosine 1-phosphate biology: the role of lipid phosphate phosphatases[J]. Semin Cell Dev Biol, 2004, 15(5): 491-501
115. Pilquil C, Dewald J, Cherney A, et al. Lipid phosphate phosphatase-1 regulates lysophosphatidate-induced fibroblast migration by controlling phospholipase D2-dependent phosphatidate generation[J]. J Biol Chem, 2006, 281(50): 38418-38429
116. Tang X, Benesch MG, Dewald J, et al. Lipid phosphate phosphatase-1 expression in cancer cells attenuates tumor growth and metastasis in mice[J]. J Lipid Res, 2014, 55(11): 2389-2400
117. Tanyi JL, Hasegawa Y, Lapushin R, et al. Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer[J]. Clin Cancer Res, 2003, 9(10 Pt 1): 3534-3545
118. Tanyi JL, Morris AJ, Wolf JK, et al. The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer[J]. Cancer Res, 2003, 63(5): 1073-1082
119. Chatterjee I, Humtsoe JO, Kohler EE, et al. Lipid phosphate phosphatase-3 regulates tumor growth via beta-catenin and CYCLIN-D1 signaling[J]. Mol Cancer, 2011, 10(1): 51
120. Nakayama J, Raines TA, Lynch KR, et al. Decreased peritoneal ovarian cancer growth in mice lacking expression of lipid phosphate phosphohydrolase 1[J]. PLoS One, 2015, 10(3): e0120071
121. Morris KE, Schang LM, Brindley DN. Lipid phosphate phosphatase-2 activity regulates S-phase entry of the cell cycle in Rat2 fibroblasts[J]. J Biol Chem, 2006, 281(14): 9297-9306
122. Flanagan JM, Funes JM, Henderson S, et al. Genomics screen in transformed stem cells reveals RNASEH2A, PPAP2C, and ADARB1 as putative anticancer drug targets[J]. Mol Cancer Ther, 2009, 8(1): 249-260
123. Brindley DN, Pilquil C. Lipid phosphate phosphatases and signaling[J]. J Lipid Res, 2009, 50 Suppl: S225-230
124. Beck A, Wurch T, Bailly C, et al. Strategies and challenges for the next generation of therapeutic antibodies[J]. Nat Rev Immunol, 2010, 10(5): 345-352
125. Fleming JK, Wojciak JM, Campbell M-A, et al. Biochemical and Structural Characterization of Lysophosphatidic Acid Binding by a Humanized Monoclonal Antibody[J]. J Mol Biol, 2011, 408(3): 462-476
126. Goldshmit Y, Matteo R, Sztal T, et al. Blockage of Lysophosphatidic Acid Signaling Improves Spinal Cord Injury Outcomes[J]. The American Journal of Pathology, 2012, 181(3): 978-992
127. Crack PJ, Zhang M, Morganti-Kossmann MC, et al. Antilysophosphatidic acid antibodies improve traumatic brain injury outcomes[J]. J Neuroinflammation, 2014, 11: 37
128. ClinicalTrials.gov. A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Lpathomab in Subjects With Neuropathic Pain[J] 2015, https://clinicaltrials.gov/show/NCT02341508
129. Rancoule C, Pradere JP, Gonzalez J, et al. Lysophosphatidic acid-1-receptor targeting agents for fibrosis[J]. Expert Opin Investig Drugs, 2011, 20(5): 657-667
130. Gross TJ, Hunninghake GW. Idiopathic Pulmonary Fibrosis[J]. N Engl J Med, 2001, 345(7): 517-525
131. Tang N, Zhao Y, Feng R, et al. Lysophosphatidic acid accelerates lung fibrosis by inducing differentiation of mesenchymal stem cells into myofibroblasts[J]. J Cell Mol Med, 2014, 18(1): 156-169
132. Swaney JS, Chapman C, Correa LD, et al. A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model[J]. Br J Pharmacol, 2010, 160(7): 1699-1713
133. ClinicalTrials.gov. Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis[J] 2015, https://clinicaltrials.gov/ct2/show/NCT01766817
134. Bradford WZ. Pirfenidone and anti-fibrotic therapy in selected patients [J], 2012: Patent (WO2012162592)
135. ClinicalTrials.gov. Proof of Biological Activity of SAR100842 in Systemic Sclerosis[J] 2014, https://clinicaltrials.gov/ct2/show/NCT01651143
136. Pattanaik D, Postlethwaite AE. A role for lysophosphatidic acid and sphingosine 1-phosphate in the pathogenesis of systemic sclerosis[J]. Discov Med, 2010, 10(51): 161-167
137. Tokumura A, Carbone LD, Yoshioka Y, et al. Elevated serum levels of arachidonoyl-lysophosphatidic acid and sphingosine 1-phosphate in systemic sclerosis[J]. Int J Med Sci, 2009, 6(4): 168-176
138. Castelino FV, Seiders J, Bain G, et al. Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma[J]. Arthritis Rheum, 2011, 63(5): 1405-1415
139. Imai A, Furui T, Tamaya T, et al. A gonadotropin-releasing hormone-responsive phosphatase hydrolyses lysophosphatidic acid within the plasma membrane of ovarian cancer cells[J]. J Clin Endocrinol Metab, 2000, 85(9): 3370-3375
140. Gierse J, Thorarensen A, Beltey K, et al. A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation[J]. J Pharmacol Exp Ther, 2010, 334(1): 310-317
141. Barbayianni E, Magrioti V, Moutevelis-Minakakis P, et al. Autotaxin inhibitors: a patent review[J]. Expert Opin Ther Pat, 2013, 23(9): 1123-1132
142. Albers HM, Ovaa H. Chemical evolution of autotaxin inhibitors[J]. Chem Rev, 2012, 112(5): 2593-2603
143. North EJ, Howard AL, Wanjala IW, et al. Pharmacophore development and application toward the identification of novel, small-molecule autotaxin inhibitors[J]. J Med Chem, 2010, 53(8): 3095-3105
144. Teo K, Brunton VG. The role and therapeutic potential of the autotaxin-lysophosphatidate signalling axis in breast cancer[J]. Biochem J, 2014, 463(1): 157-165
145. Bhave SR, Dadey DY, Karvas RM, et al. Autotaxin Inhibition with PF-8380 Enhances the Radiosensitivity of Human and Murine Glioblastoma Cell Lines[J]. Front Oncol, 2013, 3(236): 00236
146. Schleicher SM, Thotala DK, Linkous AG, et al. Autotaxin and LPA receptors represent potential molecular targets for the radiosensitization of murine glioma through effects on tumor vasculature[J]. PLoS One, 2011, 6(7): e22182
147. Saga H, Ohhata A, Hayashi A, et al. A novel highly potent autotaxin/ENPP2 inhibitor produces prolonged decreases in plasma lysophosphatidic acid formation in vivo and regulates urethral tension[J]. PLoS One, 2014, 9(4): e93230
148. Venkatraman G, Benesch MG, Tang X, et al. Lysophosphatidate signaling stabilizes Nrf2 and increases the expression of genes involved in drug resistance and oxidative stress responses: implications for cancer treatment[J]. FASEB J, 2015, 29(3): 772-785
149. Wang XJ, Sun Z, Villeneuve NF, et al. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2[J]. Carcinogenesis, 2008, 29(6): 1235-1243
150. Dunn L, Prosser HC, Tan JT, et al. Murine model of wound healing[J]. J Vis Exp, 2013(75): e50265
151. Ma L, Uchida H, Nagai J, et al. Evidence for de novo synthesis of lysophosphatidic acid in the spinal cord through phospholipase A2 and autotaxin in nerve injury-induced neuropathic pain[J]. J Pharmacol Exp Ther, 2010, 333(2): 540-546
152. Thomas Hess C. Checklist for Factors Affecting Wound Healing[J]. Advances in Skin & Wound Care, 2011, 24(4): 192 110.1097/1001.ASW.0000396300.0000304173.ec